You are here: Industry Insights > CAR-T Therapy

News List

Immuno-Oncology: Current Market Landscape and Future Trends（1） Neeta Ratanghayra
September 18, 2024
Immune Checkpoint Inhibitors & Challenges and Future Directions.
Domestic Enterprises Have Fully Laid out the Blue Ocean of US$10 Billion, and CAR-T Therapy Must Overcome the Achilles' Heel of Solid Tumor 203 Spuer/PharmaSources
August 07, 2023
The solid tumor is one of the two most deeply developed fields in CAR-T therapy, thus it is extremely urgent to overcome solid tumor in CAR-T therapy, considering domestic market access policy and current biomedical capital environment.
With Sky-high Price, CAR-T Therapy Sold at Least USD1.709 Billion in 2021 PharmaSources/Yi
March 30, 2022
Currently, six CART-cell immunotherapies have been approved in China and abroad, as shown in the table below. Except for Abecma, the other five therapies are all targeted at CD19.
The Second CAR-T Therapy in China Applied for Marketing PharmaSources/Dopine
July 01, 2020
On June 30, according to the official website of CDE, the marketing application of a CAR-T therapy, JWCAR029 by JW Therapeutics was accepted by CDE.
GenScript and InnoBation Enter into the Agreement for CAR-T therapy prnasia
December 15, 2020
A global leading biotech company GenScript Biotech Corporation announces that it has reached the agreement for cell line development and engineering, manufacture service of GMP Plasmids and Lentivirus with InnoBation Co., Ltd. a company that ...
First-in-human universal CAR-T therapy trial begins europeanpharmaceuticalreview
December 08, 2020
The dose-finding trial will evaluate the safety and activity of UniCAR-T-PSMA in up to 16 patients with advanced relapsed/refractory, PSMA-positive solid tumours.
Novartis’ CAR-T therapy Kymriah hits endpoint in follicular lymphoma trial pharmatimes
August 05, 2020
Novartis has revealed positive results from a phase 2 study of its CAR-T therapy Kymriah (tisagenlecleucel) in patients with relapsed or refractory follicular lymphoma.
FDA refuse to file BMS/bluebird bio's CAR-T therapy pharmatimes
May 14, 2020
US regulators have refused to file Bristol Myers Squibb and bluebird bio's marketing application seeking approval of idecabtagene vicleucel (ide-cel) for patients with heavily pre-treated relapsed and refractory multiple myeloma.
NICE recommends NHS use of Kymriah for second indication pharmaceutical-technology
February 03, 2019
The UK’s pricing regulator the National Institute for Health and Care Excellence (NICE) has recommended Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) for use by the National Health Service (NHS)
Global 2-year trial reports on CAR-T therapy to treat DLBCL europeanpharmaceuticalreview
December 04, 2018
A study has reported results of a clinical trial using CAR-T therapy where over half of the cancer patients were alive two year after the start…

Previous page 1 2 3 Next page